Can Cipla challenge the dominance of GSK's Advair?
This article was originally published in Scrip
Executive Summary
A generic challenge to GlaxoSmithKline's top-selling asthma drug, Advair (fluticasone plus salmeterol), may be on the way, with India's Cipla claiming that its generic product offers "identical activity" to Advair and that its delivery system could match GSK's Diskus, the intricate device through which the combination is inhaled.